Althera Pharms Company Profile

What is the competitive landscape for ALTHERA PHARMS

ALTHERA PHARMS has two approved drugs.

There are two US patents protecting ALTHERA PHARMS drugs.

There are seven patent family members on ALTHERA PHARMS drugs in ten countries and fourteen supplementary protection certificates in eight countries.

Summary for Althera Pharms

International Patents:	7
US Patents:	2
Tradenames:	2
Ingredients:	2
NDAs:	2

Drugs and US Patents for Althera Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Althera Pharms	LYPQOZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	206084-004	Apr 26, 2017		RX	No	Yes
Althera Pharms	LYPQOZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	206084-001	Apr 26, 2017		RX	No	No
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-003	Mar 23, 2021		DISCN	Yes	No	10,376,470		Y
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-004	Mar 23, 2021		DISCN	Yes	No	9,763,885		Y
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-003	Mar 23, 2021		DISCN	Yes	No	9,763,885		Y

International Patents for Althera Pharms Drugs

Country	Patent Number	Estimated Expiration
Cyprus	1123091
European Patent Office	2844233
Mexico	365046
Poland	2844233
Slovenia	2844233

Supplementary Protection Certificates for Althera Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	03C0028	France		PRODUCT NAME: EZETIMIBE; NAT. REGISTRATION NO/DATE: NL28237 20030611; FIRST REGISTRATION: DE - 54486.00.00 A 54489.00.00 20021017
0720599	05C0040	France		PRODUCT NAME: EZETIMIBE; SIMVASTATINE; NAT. REGISTRATION NO/DATE: NL 31849 20050728; FIRST REGISTRATION: DE - 58 878 00 00 20040402
0247633	62/1997	Austria		PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
0720599	92545	Luxembourg		PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
0247633	C970034	Netherlands		PRODUCT NAME: ATORVASTATINUM,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF VAN HET INWENDIGE DELTA-LACTON, IN HET BIJZONDER ATORVASTATINUM CALCICUM TRIHYDRICUM; NAT. REGISTRATION NO/DATE: RVG 21081 - RVG 21083 19970421; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Althera Pharms

Althera Pharmaceuticals: A Rising Star in the Heart Health Sector

Althera Pharmaceuticals has emerged as a notable player in the pharmaceutical industry, particularly in the realm of heart health. Founded in 2010, this innovative company has quickly established itself as a leader in developing combination medicines for cardiology and diabetes[1]. With a strong focus on patient-centered care and a commitment to research and development, Althera is making significant strides in the competitive pharmaceutical landscape.

Company Overview

Althera Pharmaceuticals is dedicated to the development and supply of innovative, patient-focused medicines. Since its inception, the company has expanded its reach, with its products now available in over 35 countries worldwide[1]. This global presence underscores Althera's commitment to improving patient health on an international scale.

Market Position

Global Reach

Althera's medicines have gained approval and are accessible to patients in more than 35 countries across the globe. The company has strategically positioned itself in major European markets and emerging markets, including Asia, Latin America, and Africa[1]. This extensive geographical coverage demonstrates Althera's strong market position and its ability to navigate diverse regulatory environments.

Therapeutic Focus

Althera has carved out a niche for itself in the therapeutic areas of cardiology and diabetes. By concentrating on these critical health sectors, the company has been able to develop specialized expertise and build a reputation for innovative solutions in these fields.

Strengths and Competitive Advantages

Innovative Combination Medicines

One of Althera's key strengths lies in its development of innovative combination medicines. This approach allows the company to address complex health issues more effectively, potentially improving patient outcomes and adherence to treatment regimens.

Strong R&D Capabilities

Althera's commitment to research and development is evident in its ability to create innovative and cost-effective medications. The company's strong R&D capabilities enable it to stay at the forefront of pharmaceutical advancements, particularly in its focus areas of cardiology and diabetes[1].

Network of Manufacturing Sites

Althera's network of manufacturing sites contributes to its ability to supply medications efficiently and cost-effectively. This infrastructure supports the company's global distribution efforts and helps maintain quality control across its product line.

B2B Partnerships

Althera works closely with B2B partners to make its products available across various geographies[1]. These partnerships likely contribute to the company's expanded reach and may provide additional resources and expertise in different markets.

Strategic Insights

Focus on Emerging Markets

Althera's presence in emerging markets, including Asia, Latin America, and Africa, positions the company to capitalize on the growing healthcare needs in these regions. As these markets continue to develop, Althera may find significant opportunities for growth and expansion.

Emphasis on Cost-Effective Solutions

By focusing on innovative and cost-effective supply of medications, Althera addresses a critical need in the healthcare industry. This approach may give the company a competitive edge, particularly in markets where healthcare affordability is a significant concern.

Potential for Further Expansion

Given Althera's success in expanding to over 35 countries since its founding in 2010, there may be potential for further geographical expansion. The company could explore entering new markets or deepening its presence in existing ones.

Challenges and Opportunities

Competitive Landscape

The pharmaceutical industry, particularly in the areas of cardiology and diabetes, is highly competitive. Althera faces competition from both established pharmaceutical giants and other innovative startups. Staying ahead in this landscape requires continuous innovation and strategic positioning.

Regulatory Hurdles

As a company operating in multiple countries, Althera must navigate various regulatory environments. While challenging, this also presents an opportunity for the company to develop expertise in global pharmaceutical regulations.

Potential for Diversification

While Althera's focus on cardiology and diabetes has served it well, there may be opportunities to diversify into related therapeutic areas. This could help the company mitigate risks associated with a narrow focus and open up new avenues for growth.

Future Outlook

Althera Pharmaceuticals appears well-positioned for continued growth in the heart health sector. Its focus on innovation, strong R&D capabilities, and global presence provide a solid foundation for future success. As the company continues to expand its reach and develop new combination medicines, it has the potential to significantly impact patient care in cardiology and diabetes treatment worldwide.

"Althera's medicines are approved and available to patients in more than 35 countries worldwide."[1]

This global reach, combined with Althera's innovative approach to developing combination medicines, positions the company as a rising star in the pharmaceutical industry, particularly in the heart health sector.

Key Takeaways

• Althera Pharmaceuticals, founded in 2010, has quickly established itself as a leader in developing combination medicines for cardiology and diabetes.
• The company's products are available in over 35 countries, demonstrating its strong global presence.
• Althera's focus on innovative combination medicines and strong R&D capabilities are key competitive advantages.
• The company's strategic presence in emerging markets positions it for potential future growth.
• Althera's emphasis on cost-effective solutions addresses a critical need in the healthcare industry.
• While facing challenges in a competitive landscape, Althera's focused approach and global reach provide a solid foundation for future success.

FAQs

1. What are Althera Pharmaceuticals' main therapeutic areas of focus? Althera Pharmaceuticals primarily focuses on developing medicines for cardiology and diabetes.

2. How many countries are Althera's products available in? Althera's medicines are approved and available in more than 35 countries worldwide.

3. What sets Althera apart from other pharmaceutical companies? Althera distinguishes itself through its focus on innovative combination medicines, strong R&D capabilities, and presence in both major European markets and emerging markets.

4. When was Althera Pharmaceuticals founded? Althera Pharmaceuticals was founded in 2010.

5. Does Althera manufacture its own medications? Yes, Althera has a network of manufacturing sites that enable innovative and cost-effective supply of medications.

Sources cited: [1] https://www.altherapharma.com